CIBC World Markets Inc. Acquires Shares of 9,300 TESARO Inc (TSRO)
CIBC World Markets Inc. acquired a new stake in TESARO Inc (NASDAQ:TSRO) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 9,300 shares of the biopharmaceutical company’s stock, valued at approximately $771,000.
A number of other institutional investors and hedge funds have also modified their holdings of TSRO. Exane Derivatives purchased a new position in shares of TESARO in the third quarter valued at approximately $106,000. Nordea Investment Management AB purchased a new position in shares of TESARO in the second quarter valued at approximately $167,000. Toronto Dominion Bank lifted its position in shares of TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 1,130 shares in the last quarter. Achmea Investment Management B.V. purchased a new position in shares of TESARO in the second quarter valued at approximately $234,000. Finally, Commonwealth Equity Services Inc purchased a new position in shares of TESARO in the third quarter valued at approximately $222,000.
In related news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 34.60% of the company’s stock.
TESARO Inc (NASDAQ TSRO) opened at $58.17 on Thursday. TESARO Inc has a 1 year low of $57.81 and a 1 year high of $192.94. The company has a market capitalization of $3,160.00, a P/E ratio of -6.90 and a beta of 1.25. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.